QuintilesIMS Forms New Collaboration With Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, And Pfizer To Generate Real World Insights On Usage Of Anti-Cancer Therapies Across Europe

QuintilesIMS (NYSE:Q) announced today that it will lead a collaborative initiative involving founding partners Bristol-Myers Squibb, Eli Lilly and Company, Merck KGaA, Darmstadt, Germany and Pfizer, which aims to provide clearer and more proactive insight into how anti-cancer treatments are used in a real-world setting across key European markets.

Currently, there are major information gaps and inconsistencies in knowledge about the real-world use of oncology products across Europe. Additional information about how oncology products are actually used, for which types of patients, with what sequences and combinations of therapies, and in which indications, is particularly important to help improve oncology patient care.

Treatment use information is typically based on historical data, thereby providing a view of the past, not a view of current practice. This new initiative is intended to provide more timely, consistent and comprehensive data resources that could be used to provide further insight for healthcare systems to make better informed decisions on patient care in the future. Importantly, substantial steps have been taken to obtain these insights while respecting individual privacy.

With more than 1.7 million deaths and three million new cases each year, cancer is a leading cause of death and morbidity in Europe, second only to cardiovascular disease 1. This new collaboration provides a partnership approach that is critical to address this challenge.

1. World Health Organization (WHO) Europe Region, Cancer, data and statistics ( http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer/data-and-statistics)

About QuintilesIMS

QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles and IMS Health, QuintilesIMS's approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes and enhanced clinical trial outsourcing through treatment innovations, care provision and access can leverage QuintilesIMS's broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial bringing clients a unique opportunity to realize the full potential of innovations and advance healthcare outcomes.

If you liked this article you might like

SBA Communications, Quintiles IMS Holdings to Be Added to S&P 500

Parexel Is Discovering the Drugs of the Future

Analysts' Actions -- Arista, Capital One, Avis, Workday and More

Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More